Endocrine Abstracts

Introduction: Prolactinoma is the most commonly occurring hormonally active pituitary tumor. In most cases, dopamine receptor agonists (DA) as a monotherapy are effective. However, approximately 10% of patients with prolactinomas fail to achieve normalization of serum prolactin levels during treatment with DA, which indicates resistance to this group of drugs.Aims: The goal was to study the pharmacokinetics of cabergoline in patients harboring prolactino...

Prolactinomas are the most common hormone-active pituitary tumors, most common in young women, whose main reason for going to the doctor is menstrual irregularity. At the onset of the disease before puberty in children, there is a delay in sexual development, in girls primary amenorrhea.A 27-year old woman has been observed since 15 years, when hyperprolactinemia was first detected, level of PRL was 10 900 IU/l, and according to MRI pituitary endose...

Experience in complex therapy of selective and non-selective dopamine agonists in women with resistant prolactinomas for recovering of ovulation function.Introduction: Prolactinomas are the most common pituitary adenomas and dopamine agonists (DA) still remain the first choice of treatment. Nevertheless, it does not always exert an adequate effect and endocrinologists face the challenge of resistant prolactinomas more frequently. This problem is very imp...

Introduction: Approximately 20% of patients with prolactinomas do not respond satisfactory (resistant) even to high dose dopamine agonist treatment. Worth noticing that there are no clear prognostic signs of treatment’s resistance as well as its etiology is a subject of discussion. Aim: The aim of our study was to assessabsorption and metabolism of cabergoline in patients with dopamine agonist-resistant prolactinomas.Materials...

Introduction: Prolactinomas are the most common type of pituitary adenomas(40% of them), representing a significant cause of infertility and hypogonadism. About 20% of patients with prolactinomas don’t respond satisfactory(i.e. resistant) even to high dose dopamine agonist(DA) treatment(>3.5–4.5 mg/week). Worth noticing that there are no clear signs to anticipate this resistance but to stepwise increase the dose of DA. In addition, the etiology of resistance &#15...

Introduction: The aim of our study was to investigate clinical and morphological features of dopamine agonist-resistant prolactinomas.Methods/design: The study included 51 patients (38 women, 13 men) with prolactin-secreting pituitary adenoma that is resistant to treatment with dopamine agonists, age 15–82 years.Results: Median of the serum PRL level distribution at the onset of the disease was 4500 mIU/l (3480, 140 300). The ...